Payment overview · 2025
General Payments
$1,787.79
101 reported records · 26 companies
Healthcare provider profile · identity verified
Caleb Vass, D.O
Allopathic & Osteopathic Physicians|Family Medicine · DUBLIN, VA · NPI 1588198949
Verified facts
What the public records show
CMS Open Payments records show Caleb Vass, D.O received $1,787.79 in general payments during 2025 across 101 reported records.
Novo Nordisk Inc accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $234.86 | 13.1% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $193.75 | 10.8% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $187.32 | 10.5% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $178.61 | 10.0% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.58 | 8.1% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $105.32 | 5.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $92.75 | 5.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.89 | 4.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $73.95 | 4.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.58 | 3.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.67 | 2.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.43 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.70 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.01 | 2.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.41 | 1.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $32.23 | 1.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.71 | 1.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.04 | 1.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.79 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.61 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.58 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.59 | 1.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.58 | 0.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $13.64 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,787.79 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $193.75 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $186.18 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $147.79 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.21 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $138.37 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $138.37 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.11 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $97.17 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.53 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $89.63 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.43 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.58 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.67 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.95 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.43 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $32.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.91 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $28.71 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 101 |
| Lisinopril | Lisinopril | 353 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 349 | 117 |
| Gabapentin | Gabapentin | 296 | 88 |
| Omeprazole | Omeprazole | 247 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 66 |
| Metformin Hcl | Metformin Hcl | 186 | 53 |
| Famotidine | Famotidine | 180 | 60 |
| Furosemide | Furosemide | 171 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 51 |
| Ozempic | Semaglutide | 141 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 134 | 36 |
| Losartan Potassium | Losartan Potassium | 131 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 24 |
| Trazodone Hcl | Trazodone Hcl | 122 | 39 |
| Alprazolam | Alprazolam | 120 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 30 |
| Clonazepam | Clonazepam | 112 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 32 |
| Tramadol Hcl | Tramadol Hcl | 104 | 18 |
| Montelukast Sodium | Montelukast Sodium | 102 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Buspirone Hcl | Buspirone Hcl | 96 | 26 |
| Eliquis | Apixaban | 88 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 27 |
| Simvastatin | Simvastatin | 87 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 24 |
| Jardiance | Empagliflozin | 83 | 28 |
| Prednisone | Prednisone | 83 | 62 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 20 |
| Sertraline Hcl | Sertraline Hcl | 72 | 27 |
| Potassium Chloride | Potassium Chloride | 71 | 25 |
| Allopurinol | Allopurinol | 70 | 24 |
| Carvedilol | Carvedilol | 70 | 23 |
| Aripiprazole | Aripiprazole | 67 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Baclofen | Baclofen | 65 | 13 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 29 |
| Spironolactone | Spironolactone | 64 | 17 |
| Pregabalin | Pregabalin | 63 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 19 |
| Diazepam | Diazepam | 60 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 15 |
| Valsartan | Valsartan | 56 | 17 |
| Meloxicam | Meloxicam | 55 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 17 |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Ezetimibe | Ezetimibe | 46 | 19 |
| Lovastatin | Lovastatin | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 17 |
| Glipizide | Glipizide | 42 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Glimepiride | Glimepiride | 38 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 12 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 35 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Topiramate | Topiramate | 32 | 11 |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 17 |
| Ondansetron Odt | Ondansetron | 28 | 17 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 12 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | 12 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Nystatin | Nystatin | 24 | 13 |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Atenolol | Atenolol | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Naproxen | Naproxen | 21 | 11 |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,787.79 · 101 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, ARISTADA, BREZTRI, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ETERNA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, LINZESS, LYBALVI, MOUNJARO, NEXLETOL, NP Thyroid 60, NURTEC ODT, NUZYRA, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error